Stimulant mechanisms of cathinones - Effects of mephedrone and other cathinones on basal and electrically evoked dopamine efflux in rat accumbens brain slices

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 54, Issue , 2014, Pages 122-130

  Opacka Juffry, Jolanta ^a   Pinnell, Thomas ^b   Patel, Nisha ^b   Bevan, Melissa ^b   Meintel, Meghan ^a   Davidson, Colin ^b  

^a UNIVERSITY OF ROEHAMPTON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Amphetamine; Bupropion; Cocaine; Diethylpropion; Ethcathinone; Voltammetry

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; 4' METHYLMETHCATHINONE; AMFEBUTAMONE; AMFEPRAMONE; AMPHETAMINE; CATHINONE DERIVATIVE; CENTRAL STIMULANT AGENT; COCAINE; DOPAMINE TRANSPORTER; ETHCATHINONE; UNCLASSIFIED DRUG; 2-ETHYLAMINO-1-PHENYL-PROPAN-1-ONE; AMPHETAMINE DERIVATIVE; DOPAMINE; METHAMPHETAMINE; PROPIOPHENONE DERIVATIVE; RADIOACTIVE IODINE;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; DOPAMINE BRAIN LEVEL; DOPAMINE EFFLUX; DOPAMINE METABOLISM; DOPAMINE RELEASE; ELECTROSTIMULATION; LIGAND BINDING; MALE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PROTEIN BINDING; RAT; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MICROELECTRODE; PHYSIOLOGY; RADIOASSAY; TISSUE CULTURE TECHNIQUE; WISTAR RAT;

AMPHETAMINE; AMPHETAMINES; ANIMALS; BUPROPION; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; DIETHYLPROPION; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; IODINE RADIOISOTOPES; MALE; METHAMPHETAMINE; MICROELECTRODES; NUCLEUS ACCUMBENS; PROPIOPHENONES; RADIOLIGAND ASSAY; RATS, WISTAR; TISSUE CULTURE TECHNIQUES;

EID: 84902505081     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.04.009     Document Type: Article

References (71)

1. Aarde S.M., Angrish D., Barlow D.J., Wright M.J.Jr, Vandewater S.A., Creehan K.M., et al. Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict Biol 2013, 8:786-799.
2. ACMD Report on consideration of the cathinones 2010, [https://www.gov.uk/government/publications/acmd-report-on-the-consideration-of-the-cathinones (accessed on November 27th 2013)].
3. Alim T.N., Rosse R.B., Vocci F.J., Lindquist T., Deutsch S.L. Diethylpropion pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence: A test of the cocaine-agonist hypothesis. Clin Neuropharmacol 1995, 18:183-195.
4. Arias H.R., Santamaría A., Ali S.F. Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol 2009, 88:223-255.
5. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
6. Berridge C.W. Neural substrates of psychostimulant-induced arousal. Neuropsychopharmacology 2006, 31:2332-2340.
7. Cameron K., Kolanos R., Verkariya R., De Felice L., Glennon R.A. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter. Psychopharmacology 2013, 227:493-499.
8. Camilleri A., Johnston M.R., Brennan M., Davis S., Caldicott D.G.E. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, α-phthalimidopropiophenone and N-ethylcathinone. Forensic Sci Int 2010, 197:59-66.
9. Cardinal R.N., Pennicott D.R., Sugathapala C.L., Robbins T.W., Everitt B.J. Impulsive choice induced in rats by lesions of the nucleus accumbens core. Science 2001, 292:2499-2501.
10. Carhart-Harris R.L., King L.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend 2011, 118:19-22.
11. Cercato C., Roizenblatt V.A., Leança C.C., Segal A., Lopes Filho A.P., Mancini M.C., et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes 2009, 33:857-865.
12. Cohen S. Diethylpropion (Tenuate): An infrequently abused anorectic. Psychosomatics 1977, 18:28-33.
13. Davidson C., Ramsey J. Desoxypipradrol is more potent than cocaine on evoked dopamine efflux in the nucleus accumbens. J Psychopharmacol 2012, 26:1036-1041.
14. Davidson C., Stamford J.A. Neurochemical evidence of functional A10 dopamine terminals innervating the ventromedial axis of the neostriatum: In vitro voltammetric data in rat brain slices. Brain Res 1993, 615:229-239.
15. Davidson C., Chauhan N.K., Knight S., Gibson C.L., Young A.M.J. Modelling ischaemia in vitro: Effects of temperature and glucose concentration on dopamine release evoked by oxygen and glucose depletion in a mouse brain slice model of ischaemic brain damage. J Neurosci Methods 2011, 202:165-172.
16. Dawson P., Opacka-Juffry J., Moffatt J.D., Daniju Y., Dutta N., Ramsey J., et al. The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Prog Neuropharmacol Biol Psychiatry 2014, 48:57-63.
17. Deluca P., Davey Z., Corazzo O., Di Furia L., Farre M., Fleslan L.H., et al. Identifying emerging trends in recreational drug use: Outcomes from the Psychonaut web mapping project. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:221-226.
18. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci 1988, 85:6274-6278.
19. Ferris M.J., Calipari E.S., Mateo Y., Melchior J.R., Roberts D.C.S., Jones S.R. Cocaine self-administration produces pharmacodynamic tolerance: Differential effects on the potency of dopamine transporter blockers, releasers, and methylphenidate. Neuropsychopharmacology 2012, 37:1708-1716.
20. Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R., et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989, 4:371-377.
21. Gorelick D.A. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 1997, 42:995-997.
22. Grandi S.M., Shimony A., Eisenberg M.J. Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Can J Cardiol 2013, 29:1704-1711.
23. Gregg R.A., Rawls S.M. Behavioral pharmacology of designer cathinones: A review of the preclinical literature. Life Sci 2013, [pii: S0024-3205(13)00680-2]. 10.1016/j.lfs.2013.10.033.
24. Gregg R.A., Tallarida C.S., Reitz A.B.., Rawls S.M. Mephedrone interactions with cocaine: Prior exposure to the 'bath salt' constituent enhances cocaine-induced locomotor activation in rats. Behav Pharmacol 2013, 24:684-688.
25. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C., et al. 4-Methylmethcathinone (mephedrone): Neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011, 339:530-536.
26. Herdon H., Strupish J., Nahorski S. Differences between the release of radiolabelled and endogenous dopamine from superfused rat brain slices: Effects of depolarizing stimuli, amphetamine and synthesis inhibition. Brain Res 1985, 348:309-320.
27. Hilfiker S., Pieribone V.A., Czernik A.J., Kao H.T., Augustine G.J., Greengard P. Synapsins as regulators of neurotransmitter release. Philos Trans R Soc Lond B Biol Sci 1999, 354:269-279.
28. Iversen L., Gibbons S., Treble R., Setola V., Huang X.P., Roth B.L. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 2013, 700:147-151.
29. Jasinski D.R., Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009, 23:419-427.
30. Jones S.R., Garris P.A., Wightman R.M. Different effects of cocaine and nomifensine on dopamine uptake in the caudate-putamen and nucleus accumbens. J Pharmacol Exp Ther 1995, 274:396-403.
31. Kapitány-Fövény M., Kertész M., Winstock A., Deluca P., Corazza O., Farkas J., et al. Substitutional potential of mephedrone: An analysis of the subjective effects. Hum Psychopharmacol 2013, 28:308-316.
32. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 2011, 164:1949-1958.
33. Lamb R.J., Griffiths R.R. Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology 1990, 102:183-190.
34. Lee T.H., Balu R., Davidson C., Ellinwood E.H. Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors. Synapse 2001, 41:301-310.
35. Lee T.H., Gee K.R., Davidson C., Ellinwood E.H. Direct, real-time assessment of dopamine release autoinhibition in the rat caudate-putamen. Neuroscience 2002, 112:647-654.
36. Lile J.A., Nader M.A. The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models. Curr Neuropharmacol 2003, 1:21-46.
37. Mair I.D., Lambert J.J., Yang J., Dempster J., Peters J.A. Pharmacological characterization of a rat 5-hydroxytryptamine type 3 receptor subunit (r5-HT3A(b)) expressed in Xenopus laevis oocytes. Br J Pharmacol 1998, 124:1667-1674.
38. Nicolaysen L.C., Pan H.T., Justice J.B. Extracellular cocaine and dopamine concentrations are linearly related in rat striatum. Brain Res 1988, 456:317-323.
39. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Elsevier Academic Press. 5th Edition.
40. Pettit H.O., Pan H.T., Parsons L.H., Justice J.B. Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem 1990, 55:798-804.
41. Phillips P.E.M., Hancock P.J., Stamford J.A. Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release. Synapse 2002, 44:15-22.
42. Prosser J.M., Nelson L.S. The toxicology of bath salts: A review of synthetic cathinones. J Med Toxicol 2012, 8:33-42.
43. Ritz M.C., Cone E.J., Kuhar M.J. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: A structure-activity study. Life Sci 1990, 46:635-645.
44. Robinson D.L., Venton B.J., Heien M.L.A.V., Wightman R.M. Detecting subsecond dopamine release with fast-scan cyclic voltammetry in vivo. Clin Chem 2003, 49:1763-1773.
45. Rocha B.A., Fumagalli F., Gainetdinov R.R., Jones S.R., Ator R., Giros B., et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1998, 1:132-137.
46. Rothman R.B., Baumann M.H. Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem 2006, 6:1845-1859.
47. Santamaría A., Arias H.R. Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats. Behav Brain Res 2010, 211:132-139.
48. Schifano F., Corkery J., Ghodse A.H. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. J Clin Psychopharmacol 2012, 32:710-714.
49. Schmitz Y., Lee C.J., Schmauss C., Gonon F., Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: Effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci 2001, 21:5916-5924.
50. Schramm-Sapyta N.L., Walker Q.D., Caster J.M., Levin E.D., Kuhn C.M. Are adolescents morevulnerable to drug addiction than adults? Evidence from animal models. Psychopharmacology 2009, 206:1-21.
51. Simmler L.D., Buser T.A., Donzelli M., Schramm Y., Dieu L.H., Huwyler J., et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013, 168:458-470.
52. Singer E.A. Transmitter release from brain slices elicited by a single pulse: A powerful method to study presynaptic mechanisms. Trends Pharmacol Sci 1988, 9:274-276.
53. Sivagnanam K., Chaudari D., Lopez P., Sutherland M.E., Ramu V.K. Bath salts" induced severe reversible cardiomyopathy. Am J Case Rep 2013, 14:288-291.
54. Smith J.P., Metters J.P., Irving C., Sutcliffe O.B., Banks C.E. Forensic electrochemistry: The electroanalytical sensing of synthetic cathinone-derivatives and their accompanying adulterants in "legal high" products. Analyst 2013, 139:389-400.
55. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 2011, 49:499-505.
56. Stamford J.A., Kruk Z.L., Millar J. Dissociation of the actions of uptake blockers upon dopamine overflow and uptake in the rat nucleus accumbens: In vivo voltammetric data. Neuropharmacology 1989, 28:1383-1388.
57. Stathis M., Sceffel U., Lever S.Z., Boja J.W., Carroll F.I., Kuhar M.J. Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology 1995, 119:376-384.
58. Strazielle C., Lalonde R., Amdiss F., Botez M.I., Hébert C., Reader T.A. Distribution of dopamine transporters in basal ganglia of cerebellar ataxic mice by [125I]RTI-121 quantitative autoradiography. Neurochem Int 1998, 32:61-68.
59. Thomsen M., Hall F.S., Uhl G.R., Caine S.B. Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J Neurosci 2009, 29:1087-1092.
60. Trout S.J., Kruk Z.L. Differences in evoked dopamine efflux in rat caudate putamen, nucleus accumbens and tuberculum olfactorium in the absence of uptake inhibition: Influence of autoreceptors. Br J Pharmacol 1992, 106:452-458.
61. Vardakou I., Pistos C., Spiliopoulou C. Drugs for youth via internet and the example of mephedrone. Toxicol Lett 2011, 201:191-195.
62. Venton B.J., Seipel A.T., Phillips P.E., Wetsel W.C., Gitler D., Greengard P., et al. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci 2006, 26:3206-3209.
63. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997, 386:827-830.
64. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M., Telang F. Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications. Arch Neurol 2007, 64:1575-1579.
65. Wanat M.J., Willuhn I., Clark J.J., Phillips P.E.M. Phasic dopamine release in appetitive behaviors and drug addiction. Curr Drug Abuse Rev 2009, 2:195-213.
66. Wood D., Dargan P. Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicology. Prog Neuropsychopharmacol Biol 2012, 39:227-233.
67. Wood D.M., Davies S., Puchnarewicz M., Button J., Archer R., Ovaska H., et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010, 6:327-330.
68. Wu Q., Reith M.E.A., Kuhar M.J., Carroll F.I., Garris P.A. Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. J Neurosci 2001, 21:6338-6347.
69. Yorgason J.T., España R.A., Jones S.R. Demon voltammetry and analysis software: Analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures. J Neurosci Methods 2011, 202:158-164.
70. Yu H., Rothman R.B., Dersch C.M., Partilla J.S., Rice K.C. Uptake and Release Effects of Diethylpropion and its Metabolites with Biogenic Amine Transporters. Bioorg Med Chem 2000, 8:2689-2692.
71. Zheng F., Zhan C.G. Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse. PLoS Comput Biol 2012, 8:e1002610.